Company Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States.
It operates through two segments: Therapeutics and Contract Research.
The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.
The Contract Research segment engages in the provision of laboratory services.
The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis.
In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer.
The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Country | United States |
| IPO Date | Oct 6, 2015 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 86 |
| CEO | Dr. Neal S. Walker D.O., M.D. |
Contact Details
Address: 640 Lee Road Wayne, Pennsylvania United States | |
| Website | https://www.aclaristx.com |
Stock Details
| Ticker Symbol | ACRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001557746 |
| CUSIP Number | 00461U105 |
| ISIN Number | US00461U1051 |
| Employer ID | 46-0571712 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Neal S. Walker D.O., M.D. | Co-Founder, Interim Chief Executive Officer & Chairman |
| Dr. Hugh M. Davis Ph.D. | President, Chief Operating Officer & Director |
| Kevin Balthaser | Chief Financial Officer |
| Ajay Aggarwal M.B.A., M.D. | Senior Vice President of Clinical Development |
| Dr. Jon Jacobsen Ph.D. | Senior Vice President of Chemistry |
| Dr. Joseph Monahan Ph.D. | Chief Scientific Officer |
| Dr. Steven Knapp M.S. Pharm.D. | Executive Vice President, Regulatory Affairs & Quality Assurance |
| James Loerop | Chief Business Officer |
| Matthew Rothman J.D. | General Counsel & Corporate Secretary |
| Steve Tucker | Senior Vice President of Project Leadership |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Dec 31, 2024 | 424B3 | Filing |
| Dec 19, 2024 | S-3 | Filing |
| Dec 12, 2024 | 4 | Filing |
| Dec 06, 2024 | 4 | Filing |
| Dec 04, 2024 | D | Filing |